← Leaderboards
Yujin Hoshida
Harvard School Of Public Health
$15,069,085
Attributed
$22,536,628
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.3M · FY2010–25$20M$15M$10M$5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,788,394 · 12
By mechanism
R01$13,886,303 · 5
U01$7,965,386 · 3
P50$3,198,239 · 3
U19$2,738,466 · 1
Top collaborators
- Amit Singal11 shared
- Raymond T Chung8 shared
- Richard R Drake5 shared
- Anand S Mehta5 shared
- Anna Mae Elizabeth Diehl3 shared
- Cynthia A Moylan3 shared
- Habibul Ahsan1 shared
- Joan Siefert Brugge1 shared
Others in their field
Top investigators on “Cirrhosis”
- Russell E Ware · Duke University$30,715,534
- Hidekazu Tsukamoto · Va Greater Los Angeles Healthcare System$28,844,065
- Anna Mae Elizabeth Diehl · Johns Hopkins University$25,083,421
- Charles M. Rice · Rockefeller University$24,697,583
- Merrill E Gershwin · University Of California At Davis$23,357,355
- Raymond T Chung · Massachusetts General Hospital$18,086,371
Research focus
CirrhosisLiverBiological MarkersSerumPrimary Carcinoma Of The Liver CellsChemopreventionMalignant Neoplasm Of LiverFutureCohortEtiologyMalignant NeoplasmsSamplingLiver DiseasesMortalityDetectionMolecularTissuesBaseLiver FibrosisAffectLiver CirrhosisPrognosticScreeningPrevention
Grant awards (34)
Non-invasive etiology-adjusted precision liver cancer risk prediction$2,876,456
R01 · FY2025 · CA · contact PI
UT Southwestern Liver Cancer SPORE$2,513,300
P50 · FY2025 · CA
Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules$2,104,865
U01 · FY2025 · CA
Trial of Statins for Chemoprevention in Hepatocellular Carcinoma$1,487,531
R01 · FY2025 · CA
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis$628,059
U01 · FY2025 · CA · contact PI
Project 1: Cirrhosis-stroma-directed HCC chemoprevention with EGFR inhibition$580,523
P50 · FY2025 · CA · contact PI
Developmental Research Program$104,416
P50 · FY2025 · CA · contact PI
Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules$846,605
U01 · FY2024 · CA
Trial of Statins for Chemoprevention in Hepatocellular Carcinoma$785,064
R01 · FY2024 · CA
Epigallocatechin gallate for prevention of lethal cirrhosis complications$585,642
R01 · FY2024 · CA · contact PI
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis$323,446
U01 · FY2024 · CA · contact PI
Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver Nodules$907,163
U01 · FY2023 · CA
Epigallocatechin gallate for prevention of lethal cirrhosis complications$684,526
R01 · FY2023 · CA · contact PI
Reverse-engineering precision liver cancer chemoprevention$613,866
R01 · FY2023 · CA · contact PI
Glycopathology of HCC: identification of the source cells of serum fucosylation$603,318
U01 · FY2023 · CA
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis$366,710
U01 · FY2023 · CA · contact PI
Reverse-engineering precision liver cancer chemoprevention$199,439
R01 · FY2023 · CA · contact PI
Trial of Statins for Chemoprevention in Hepatocellular Carcinoma$1
R01 · FY2023 · CA
Trial of Statins for Chemoprevention in Hepatocellular Carcinoma$697,704
R01 · FY2022 · CA
Reverse-engineering precision liver cancer chemoprevention$616,470
R01 · FY2022 · CA · contact PI
Glycopathology of HCC: identification of the source cells of serum fucosylation$603,318
U01 · FY2022 · CA
Non-invasive monitoring of metabolic liver cancer risk$203,508
R01 · FY2022 · CA · contact PI
Trial of Statins for Chemoprevention in Hepatocellular Carcinoma$675,855
R01 · FY2021 · CA
Reverse-engineering precision liver cancer chemoprevention$629,051
R01 · FY2021 · CA · contact PI
Glycopathology of HCC: identification of the source cells of serum fucosylation$413,676
U01 · FY2021 · CA
Reverse-engineering precision liver cancer chemoprevention$623,745
R01 · FY2020 · CA · contact PI
Glycopathology of HCC: identification of the source cells of serum fucosylation$615,632
U01 · FY2020 · CA
Reverse-engineering precision liver cancer chemoprevention$653,924
R01 · FY2019 · CA · contact PI
Glycopathology of HCC: identification of the source cells of serum fucosylation$552,594
U01 · FY2019 · CA
Molecular Prognostic Indicators in Liver Cirrhosis and Cancer$683,136
R01 · FY2016 · DK · contact PI
Molecular Prognostic Indicators in Liver Cirrhosis and Cancer$683,136
R01 · FY2015 · DK · contact PI
Molecular Prognostic Indicators in Liver Cirrhosis and Cancer$696,850
R01 · FY2014 · DK · contact PI
Molecular Prognostic Indicators in Liver Cirrhosis and Cancer$490,399
R01 · FY2013 · DK · contact PI
Discovery, Biology and Risk of Inherited Variants in Breast Cancer$2,738,466
U19 · FY2010 · CA